EA201590597A1 - Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина - Google Patents

Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина

Info

Publication number
EA201590597A1
EA201590597A1 EA201590597A EA201590597A EA201590597A1 EA 201590597 A1 EA201590597 A1 EA 201590597A1 EA 201590597 A EA201590597 A EA 201590597A EA 201590597 A EA201590597 A EA 201590597A EA 201590597 A1 EA201590597 A1 EA 201590597A1
Authority
EA
Eurasian Patent Office
Prior art keywords
vaccines
protein
hbv
vaccine
helpatitis
Prior art date
Application number
EA201590597A
Other languages
English (en)
Other versions
EA036030B1 (ru
Inventor
Дэвид Б. Уэйнер
Цзянь Янь
Ниямекие Обенг-Аджей
Original Assignee
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания filed Critical Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Publication of EA201590597A1 publication Critical patent/EA201590597A1/ru
Publication of EA036030B1 publication Critical patent/EA036030B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55538—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

В настоящей заявке предлагаются последовательности нуклеиновых кислот, кодирующие коровые белки вируса гепатита В (HBV), поверхностные антигенные белки, их фрагменты и комбинации, а также генетические конструкты/векторы и вакцины, которые экспрессируют указанные белковые последовательности. Эти вакцины способны индуцировать иммунный ответ периферически и в печени с помощью набора клеточных и гуморальных агентов. В настоящей заявке предлагаются также способы профилактической и/или терапевтической иммунизации индивидуумов против HBV. Комбинированная вакцина также может быть использована для разработки индивидуальных вакцин для отдельных уровней иммунных ответов на заражение HBV.
EA201590597A 2012-09-19 2013-09-19 Иммуногенная вакцина против hbv у человека EA036030B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/622,965 US9238679B2 (en) 2011-02-11 2012-09-19 Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
PCT/US2013/060618 WO2014047286A1 (en) 2012-09-19 2013-09-19 Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same

Publications (2)

Publication Number Publication Date
EA201590597A1 true EA201590597A1 (ru) 2015-11-30
EA036030B1 EA036030B1 (ru) 2020-09-16

Family

ID=48945721

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201590597A EA036030B1 (ru) 2012-09-19 2013-09-19 Иммуногенная вакцина против hbv у человека
EA202090759A EA202090759A3 (ru) 2012-09-19 2013-09-19 Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202090759A EA202090759A3 (ru) 2012-09-19 2013-09-19 Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина

Country Status (17)

Country Link
US (2) US9238679B2 (ru)
EP (1) EP2897640B1 (ru)
JP (3) JP6795303B2 (ru)
KR (3) KR102581951B1 (ru)
CN (2) CN104640565B (ru)
AU (1) AU2013318022B2 (ru)
BR (1) BR112015005987A2 (ru)
CA (2) CA2882839C (ru)
EA (2) EA036030B1 (ru)
HK (2) HK1210702A1 (ru)
MX (2) MX363671B (ru)
NZ (1) NZ705526A (ru)
PH (1) PH12015500308A1 (ru)
SG (2) SG11201502113YA (ru)
UA (1) UA120909C2 (ru)
WO (1) WO2014047286A1 (ru)
ZA (1) ZA201501639B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032364B1 (ru) 2011-02-11 2019-05-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
WO2017176319A1 (en) 2016-04-06 2017-10-12 University Of Washington Therapeutic vaccine for hepatitis b virus (hbv) using the hbv core antigen
WO2018009553A1 (en) * 2016-07-05 2018-01-11 University Of Massachusetts Aav2-mediated gene delivery of sfasl as a neuroprotective therapy in glaucoma
CN106421774B (zh) * 2016-09-08 2019-05-28 中国科学院生物物理研究所 PreS1用于制备乙肝疫苗以及治疗慢性乙型肝炎的用途
CA3037682A1 (en) * 2016-09-21 2018-03-29 The Wistar Institute Of Anatomy And Biology Optimized synthetic consensus inmunogenic compositions targeting fibroblast activation protein
WO2018225731A1 (ja) * 2017-06-05 2018-12-13 株式会社ビークル Ｈｂｖに対する免疫応答を生じさせるために用いられるウイルス様粒子
CN111542340B (zh) * 2017-11-16 2023-12-19 华盛顿大学 治疗性乙型肝炎病毒(hbv)疫苗
US20220047695A1 (en) * 2018-12-21 2022-02-17 The Wistar Institute Of Anatomy And Biology Compositions comprising self-assembling vaccines and methods of using the same
KR102175170B1 (ko) * 2019-02-19 2020-11-05 대한민국 HBV enhancer 억제인자 ACK1을 포함하는 B형 간염 치료용 조성물
JP2022536850A (ja) * 2019-06-18 2022-08-19 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Ｂ型肝炎ウイルス（ｈｂｖ）ワクチンおよび抗ｐｄ－１または抗ｐｄ－ｌ１抗体の組合せ
CN117843811A (zh) 2019-09-30 2024-04-09 吉利德科学公司 Hbv疫苗和治疗hbv的方法
CN111494616A (zh) * 2020-04-27 2020-08-07 重庆医科大学附属永川医院 一种新冠病毒免疫增强型基因疫苗及其制备方法
WO2023133509A2 (en) * 2022-01-08 2023-07-13 Carogen Corporation Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5643579A (en) 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
ZA858044B (en) 1984-11-01 1987-05-27 American Home Prod Oral vaccines
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4790987A (en) 1985-11-15 1988-12-13 Research Corporation Viral glycoprotein subunit vaccine
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
CH682669A5 (fr) 1989-03-08 1993-10-29 Health Research Inc Virus recombinant modifié pour exprimer un produit de gènes chez un hôte, procédés et vaccin correspondants.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5591439A (en) 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
WO1990011687A1 (en) 1989-03-31 1990-10-18 Washington University VACCINES CONTAINING AVIRULENT phoP-TYPE MICROORGANISMS
EP0431668B1 (en) 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
AU7906691A (en) 1990-05-23 1991-12-10 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Adeno-associated virus (aav)-based eucaryotic vectors
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5955088A (en) 1992-02-03 1999-09-21 Cedars-Sinai Medical Center Pharmaceutical compsition of herpes simplex virus type-1 (HSV-1), glycoproteins
JP3285355B2 (ja) 1992-06-04 2002-05-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ｉｎｖｉｖｏ遺伝子治療のための方法及び組成物
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
ATE302854T1 (de) 1993-01-26 2005-09-15 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
CA2164505A1 (en) 1993-06-07 1994-12-22 Phillip W. Berman Hiv envelope polypeptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US6156319A (en) 1994-07-25 2000-12-05 The Trustees Of The University Of Pennsylvania Soluble herpesvirus glycoprotein complex vaccine
NL9401820A (nl) 1994-11-02 1996-06-03 Meyn Maschf Inrichting voor het bewerken van aan zijn poten opgehangen gevogelte.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US5650309A (en) 1995-05-16 1997-07-22 The Regents Of The University Of California Viral vectors
US5698202A (en) 1995-06-05 1997-12-16 The Wistar Institute Of Anatomy & Biology Replication-defective adenovirus human type 5 recombinant as a rabies vaccine carrier
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
ATE337794T1 (de) 1997-04-03 2006-09-15 Electrofect As Verfahren zum verabreichen von pharmazeutischen präparaten und nukleinsäuren an den skelettmuskel
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
WO1999001158A1 (fr) 1997-06-30 1999-01-14 Rhone-Poulenc Rorer S.A. Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
EP2428250A1 (en) 1998-07-13 2012-03-14 Genetronics, Inc. Skin and muscle-targeted gene therapy by pulsed electrical field
US6589529B1 (en) 1998-10-30 2003-07-08 Children's Hospital Medical Center Rotavirus subunit vaccine
AU1928201A (en) * 1999-11-24 2001-06-04 Chiron Corporation Hbv/hcv virus-like particle
US6740323B1 (en) 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
JP3543326B2 (ja) 2001-08-30 2004-07-14 ソニー株式会社 情報処理装置および方法、情報処理システム、情報配信装置、記録媒体、並びにプログラム
CA2492826C (en) 2001-09-14 2016-12-13 Cytos Biotechnology Ag Encapsulation of unmethylated cpg-containing oligonucleotides into virus-like particles: method of preparation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
ES2379346T3 (es) 2002-03-28 2012-04-25 Brenntag Biosector A/S Composiciones de vacuna combinadas de ADN/proteína
US7328064B2 (en) 2002-07-04 2008-02-05 Inovio As Electroporation device and injection apparatus
CN100381463C (zh) 2002-09-18 2008-04-16 中国人民解放军免疫学研究所 用于生产治疗用乙型肝炎疫苗或药物的免疫原及其制备方法和用途
WO2004041177A2 (en) 2002-11-04 2004-05-21 Advisys, Inc. Synthetic muscle promoters with activities exceeding naturally occurring regulatory sequences in cardiac cells
DK2364769T3 (en) 2003-05-30 2016-04-11 Vgxi Inc Apparatus and methods for biomaterialeproduktion
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
DE10339927A1 (de) * 2003-08-29 2005-03-24 Rhein Biotech Gesellschaft für neue Biotechnologische Prozesse und Produkte mbH Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
US20070026005A1 (en) * 2003-09-09 2007-02-01 Sung Young C Vaccine composition comprising il-12 adjuvant encapsulated in controlled-release microsphere
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
WO2006033679A2 (en) * 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
CN101421402A (zh) * 2006-01-11 2009-04-29 分子作物育种代理有限公司 产生转基因禾本科细胞和植物的方法
DK2399602T3 (en) * 2006-06-02 2015-02-23 Int Aids Vaccine Initiative HIV-1 clade-A CONSENSUS SEQUENCES, ANTIGENS AND TRAN GENES
WO2008089144A2 (en) 2007-01-12 2008-07-24 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Improved dna vaccination protocols
KR100836745B1 (ko) 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
WO2008103380A2 (en) * 2007-02-21 2008-08-28 Fox Chase Cancer Center Hepatitis b virus compositions and methods of use
PT2153260T (pt) 2007-05-23 2017-04-24 Vgxi Inc Composição que compreende uma alta concentração de moléculas biologicamente ativas e processos de preparação da mesma
US20090214593A1 (en) 2007-08-16 2009-08-27 Tripep Ab Immunogen platform
US8138318B2 (en) * 2007-09-13 2012-03-20 Abbott Laboratories Hepatitis B pre-S2 nucleic acid
WO2009099716A1 (en) 2008-01-11 2009-08-13 Vgx Pharmaceuticals, Inc. Novel vaccines against multiple subtypes of dengue virus
EP2331123A4 (en) * 2008-07-24 2012-11-07 Aduro Biotech COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C
WO2010016071A2 (en) 2008-08-05 2010-02-11 Swati Subodh Identification of genomic signature for differentiating highly similar sequence variants of an organism
WO2010042751A2 (en) 2008-10-08 2010-04-15 Chimeros Inc. Chimeric therapeutics, compositions, and methods for using same
WO2010050939A1 (en) 2008-10-29 2010-05-06 The Trustees Of The University Of Pennsylvania Improved hcv vaccines and methods for using the same
WO2010057159A2 (en) * 2008-11-17 2010-05-20 Vgx Pharmaceuticals, Llc Antigens that elicit immune response against flavivirus and methods of using same
CN101502650B (zh) 2009-03-10 2011-12-28 邢益平 密码子优化的乙型肝炎核酸疫苗
EP2424999A1 (en) 2009-04-30 2012-03-07 Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) Modified immunization vectors
US8298820B2 (en) 2010-01-26 2012-10-30 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
CN101954093A (zh) * 2010-09-14 2011-01-26 中国人民解放军第二军医大学 乙型肝炎核酸疫苗及其构建方法
EA032364B1 (ru) * 2011-02-11 2019-05-31 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
WO2012109404A1 (en) * 2011-02-12 2012-08-16 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis b infection

Also Published As

Publication number Publication date
KR102382942B1 (ko) 2022-04-05
EP2897640A1 (en) 2015-07-29
WO2014047286A1 (en) 2014-03-27
JP6795303B2 (ja) 2020-12-02
JP7050310B2 (ja) 2022-04-08
EP2897640B1 (en) 2022-03-23
US9675690B2 (en) 2017-06-13
MX2019003615A (es) 2019-07-18
US9238679B2 (en) 2016-01-19
CN104640565A (zh) 2015-05-20
KR102581951B1 (ko) 2023-09-22
MX2015003489A (es) 2015-06-22
CN107337719A (zh) 2017-11-10
AU2013318022B2 (en) 2017-03-09
EA202090759A2 (ru) 2020-07-31
EA202090759A3 (ru) 2020-10-30
MX363671B (es) 2019-03-29
SG10201702325UA (en) 2017-04-27
PH12015500308B1 (en) 2015-04-20
HK1210702A1 (en) 2016-05-06
CA2882839A1 (en) 2014-03-27
CN104640565B (zh) 2017-09-05
US20160114030A1 (en) 2016-04-28
EA036030B1 (ru) 2020-09-16
KR20220045080A (ko) 2022-04-12
NZ705526A (en) 2016-01-29
EP2897640A4 (en) 2016-09-07
SG11201502113YA (en) 2015-05-28
UA120909C2 (uk) 2020-03-10
JP2019163286A (ja) 2019-09-26
CA3158935A1 (en) 2014-03-27
KR20230141895A (ko) 2023-10-10
PH12015500308A1 (en) 2015-04-20
BR112015005987A2 (pt) 2017-08-08
JP2015530410A (ja) 2015-10-15
JP2022084800A (ja) 2022-06-07
AU2013318022A1 (en) 2015-03-19
HK1246318A1 (zh) 2018-09-07
US20130209395A1 (en) 2013-08-15
ZA201501639B (en) 2016-01-27
KR20150056611A (ko) 2015-05-26
CA2882839C (en) 2022-07-05
CN107337719B (zh) 2022-01-04

Similar Documents

Publication Publication Date Title
EA201590597A1 (ru) Коровый белок вируса гепатита в и поверхностный антигенный белок и содержащая их вакцина
EA201391109A1 (ru) Молекулы нуклеиновой кислоты, кодирующие новые антигены герпеса, вакцина, включающая их, и способы их использования
EA201892795A1 (ru) Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
CY1123769T1 (el) Νουκλεϊκα οξεα για την αγωγη αλλεργιων
CL2021000636A1 (es) Vacuna contra el virus de la peste porcina africana
CY1120740T1 (el) Βελτιωμενα ευλογοϊικα εμβολια
EA201690504A1 (ru) Антигенсвязывающие белки к gitr
WO2014018858A3 (en) Multimeric fusion protein vaccine and immunotherapeutic
EA201491171A1 (ru) Вещества, содержащие улучшенные генетические конструкции il-12, вакцины, иммунотерапевтические составы и способы их применения
MX346245B (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
EA201400912A1 (ru) Рекомбинантные поксвирусные векторы, экспрессирующие белки вируса бешенства и ox40, и вакцины, созданные на их основе
AR080585A1 (es) Vacunacion contra tumores que comprende una respuesta inmune humoral contra proteinas propias
MX2019003682A (es) Antigenos de consenso del virus sincitial respiratorio humano, constructos de acido nucleico y vacunas hechas de estos, y metodos para utilizarlas.
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
EA201992282A1 (ru) Усовершенствованные вакцины против вируса папилломы человека и способы их применения
MX355501B (es) Estructuras de consenso de antigenos y vacunas elaboradas a partir de estas y metodos para utilizarlas en el tratamiento de la malaria.
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
RU2012149036A (ru) Векторы парапоксвируса, содержащие антиген вируса бешенства
WO2020065349A3 (en) Vaccines and methods
EA033242B1 (ru) Усовершенствованные нуклеиновые кислоты и белки вируса человеческой папилломы, вакцины и композиции на их основе и способы индукции иммунного ответа против впч с их применением
Golshani et al. A RECOMBINANT SUBUNIT VACCINE BASED ON THE L7/L12 AND TOMP31 PROTEINS INDUCES PROTECTION AGAINST BRUCELLA INFECTION IN BALB/C MICE
AR105134A1 (es) Vacunas contra la influenza con coincidencia antigénica
TH167679B (th) โมเลกุลกรดนิวคลีอิกซึ่งเข้ารหัสโปรตีนแกนกลางไวรัสตับอักเสบชนิดบี และโปรตีนแอนติเจนพื้นผิวและวัคซีนซึ่งประกอบรวมด้วยสิ่งเดียวกัน
Arya et al. Prospective human trials with Dengue virus vaccines and the NS1 antigen production among vaccine recipients
RU2012142337A (ru) Способы получения полифункциональных молекулярных конструкций, содержащих антигенные эпитопы актуальных аллергенов и сигнальные пептиды, обладающие иммунорегуляторными свойствами

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM